September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Transcorneal electrical stimulation in patients with primary open-angle glaucoma: A prospective long-term, case-series study.
Author Affiliations & Notes
  • Yuka Ota
    Ophthalmology, Keio University, Tokyo, Japan
  • Naoki Ozeki
    Ophthalmology, Keio University, Tokyo, Japan
  • Kenya Yuki
    Ophthalmology, Keio University, Tokyo, Japan
  • Daisuke Shiba
    Ophthalmology, Keio University, Tokyo, Japan
  • Itaru Kimura
    Saitama Medical University , Saitama, Japan
  • Kazushige Tsunoda
    National Institute of Sensory organ, Tokyo, Japan
  • Kei Shinoda
    Teikyo University, Tokyo, Japan
  • Hisao Ohde
    Ophthalmology, Keio University, Tokyo, Japan
  • Kazuo Tsubota
    Ophthalmology, Keio University, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Yuka Ota, None; Naoki Ozeki, None; Kenya Yuki, None; Daisuke Shiba, None; Itaru Kimura, None; Kazushige Tsunoda, None; Kei Shinoda, None; Hisao Ohde, None; Kazuo Tsubota, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2553. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yuka Ota, Naoki Ozeki, Kenya Yuki, Daisuke Shiba, Itaru Kimura, Kazushige Tsunoda, Kei Shinoda, Hisao Ohde, Kazuo Tsubota; Transcorneal electrical stimulation in patients with primary open-angle glaucoma: A prospective long-term, case-series study.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2553.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Transcorneal electrical stimulation (TES) is reported to be effective for the treatment of retinitis pigmentosa, retinal artery occlusion, non-ishchemic optic neuropathy, traumatic optic neuropathy, and Best vitelliform macular dystrophy. We performed a prospective, long-term, case-series study to explore the safety and efficacy of TES for the treatment of primary open-angle glaucoma (POAG).

Methods : Ten eyes from 6 male subjects with POAG were enrolled in this study. Among 6 POAG patients, 4 patients had normal-tension glaucoma. Average age was 58.7 ± 15.2 years. The subjects in this study underwent TES every 2-3 months for 4 years. The procedure of TES treatment was as follows: First, the DTL electrode was placed on the lower conjunctiva. Then, the electric current pulses were delivered by a stimulator (BPG-1,BAK Electronics, Inc.) and a stimulus isolation unit (BSI-2). Next, the current of the biphasic pulses (10msec; 20Hz) was increased to determine the threshold current necessary to elicit the phosphenes. Then, the current evoking the phosphenes which the patient perceived in the whole visual area was delivered continuously for 30 min using the biphasic pulses. Ophthalmic examinations including visual field testing using Humphery visual field testing (SITA standard 30-2) were assessed according to the study plan. All the patients performed visual field testing at least three times before enrollment in this study. Changes in MD value were evaluated by linear regression model. Among ten eyes, three eyes underwent visual field test only once, therefore, we excluded these three eyes from the analysis.

Results : During the study period, TES was performed 16.9 ± 8.5 times and for 34.9 ± 17.6 months [range 6 - 48]. Average pre-TES IOP, BCVA, and MD values were 12.3 ± 1.8 mm Hg, 0.44 ± 0.66 (LogMar) and -20.7 ± 7.1 dB. The average MD value was -21.0 ± 8.6 dB (p=0.53 vs pre-TES paired t-test, 6 months), -17.4 ± 6.8 (p=0.58, 12 m), -15.9 ± 5.9 (p=0.07, 18 m), -19.4 ± 6.2 (p=0.64, 24 m), -17.0 ± 6.7 (p=0.48, 30 m), -17.0 ± 7.8 (p=0.74, 36 m) and -12.6 ± 3.9 (p=0.30, 48 m). However, positive trends were discovered (β=0.462, p=0.001) between the number of times TES was performed and the change in MD value. No serious adverse event was observed during the study period.

Conclusions : TES treatment may improve glaucomatous visual field defect in subjects with POAG.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×